Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medplus Health Services disclosed that its subsidiary Optival Health Solutions received three drug license suspension orders from Drug Control Administration authorities in Telangana and Karnataka. The violations relate to Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945. The suspensions are short-term (1 to 3 days) for stores located in Maruthi Nagar Kothapet (Telangana), Nelamangala (Karnataka), and Ganganagar (Karnataka). The total quantifiable potential revenue loss is approximately Rs 3.49 lakhs across all three stores.
The impact on Medplus financials is minimal as only three stores face temporary short suspensions with a combined revenue exposure of just Rs 3.49 lakhs. However, repeated regulatory actions could attract greater scrutiny from drug authorities and may have minor reputational implications.